288 related articles for article (PubMed ID: 21899998)
1. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.
Mostard RL; Vöö S; van Kroonenburgh MJ; Verschakelen JA; Wijnen PA; Nelemans PJ; Erckens RJ; Drent M
Respir Med; 2011 Dec; 105(12):1917-24. PubMed ID: 21899998
[TBL] [Abstract][Full Text] [Related]
2. Extent of disease activity assessed by 18F-FDG PET/CT in a Dutch sarcoidosis population.
Cremers JP; Van Kroonenburgh MJ; Mostard RL; Vöö SA; Wijnen PA; Koek GH; Drent M
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Apr; 31(1):37-45. PubMed ID: 24751452
[TBL] [Abstract][Full Text] [Related]
3. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis.
Sobic-Saranovic D; Grozdic I; Videnovic-Ivanov J; Vucinic-Mihailovic V; Artiko V; Saranovic D; Djuric-Stefanovic A; Masulovic D; Odalovic S; Ilic-Dudvarski A; Popevic S; Pavlovic S; Obradovic V
J Nucl Med; 2012 Oct; 53(10):1543-9. PubMed ID: 22879080
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting Enzyme as a Predictor of Extrathoracic Involvement of Sarcoidosis.
Yasar Z; Özgül MA; Cetinkaya E; Kargi A; Gül Ş; Talay F; Tanriverdi E; Dincer HE
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):318-24. PubMed ID: 26847099
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.
Keijsers RG; Verzijlbergen FJ; Oyen WJ; van den Bosch JM; Ruven HJ; van Velzen-Blad H; Grutters JC
Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1131-7. PubMed ID: 19259660
[TBL] [Abstract][Full Text] [Related]
6. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis.
Mostard RL; Verschakelen JA; van Kroonenburgh MJ; Nelemans PJ; Wijnen PA; Vöö S; Drent M
Respir Med; 2013 Mar; 107(3):439-47. PubMed ID: 23261309
[TBL] [Abstract][Full Text] [Related]
7. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis.
Kalkanis A; Kalkanis D; Drougas D; Vavougios GD; Datseris I; Judson MA; Georgiou E
Nucl Med Commun; 2016 Mar; 37(3):273-7. PubMed ID: 26544095
[TBL] [Abstract][Full Text] [Related]
8. A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.
Mostard RL; Van Kuijk SM; Verschakelen JA; van Kroonenburgh MJ; Nelemans PJ; Wijnen PA; Drent M
BMC Pulm Med; 2012 Sep; 12():57. PubMed ID: 22978780
[TBL] [Abstract][Full Text] [Related]
9. Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography.
Rahmi A; Deshayes E; Maucort-Boulch D; Varron L; Grange JD; Kodjikian L; Seve P
Br J Ophthalmol; 2012 Jan; 96(1):99-103. PubMed ID: 21464036
[TBL] [Abstract][Full Text] [Related]
10. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
11. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis.
Teirstein AS; Machac J; Almeida O; Lu P; Padilla ML; Iannuzzi MC
Chest; 2007 Dec; 132(6):1949-53. PubMed ID: 17925421
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients.
Mostard RL; Prompers L; Weijers RE; van Kroonenburgh MJ; Wijnen PA; Geusens PP; Drent M
Clin Nucl Med; 2012 Jan; 37(1):21-5. PubMed ID: 22157023
[TBL] [Abstract][Full Text] [Related]
13. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
[TBL] [Abstract][Full Text] [Related]
14. Use of integrated FDG-PET/CT in sarcoidosis.
Krüger S; Buck AK; Mottaghy FM; Pauls S; Schelzig H; Hombach V; Reske SN
Clin Imaging; 2008; 32(4):269-73. PubMed ID: 18603181
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study.
Ambrosini V; Zompatori M; Fasano L; Nanni C; Nava S; Rubello D; Fanti S
Clin Nucl Med; 2013 Apr; 38(4):e171-7. PubMed ID: 23429384
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Value of Serum-Soluble Interleukin 2 Receptor Levels vs Angiotensin-Converting Enzyme in Patients With Sarcoidosis-Associated Uveitis.
Groen-Hakan F; Eurelings L; ten Berge JC; van Laar J; Ramakers CRB; Dik WA; Rothova A
JAMA Ophthalmol; 2017 Dec; 135(12):1352-1358. PubMed ID: 29121154
[TBL] [Abstract][Full Text] [Related]
17.
Chauvelot P; Skanjeti A; Jamilloux Y; de Parisot A; Broussolle C; Denis P; Ramackers JM; Giammarile F; Kodjikian L; Seve P
Br J Ophthalmol; 2019 Nov; 103(11):1650-1655. PubMed ID: 30658987
[TBL] [Abstract][Full Text] [Related]
18. Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences.
Tezuka D; Haraguchi G; Ishihara T; Ohigashi H; Inagaki H; Suzuki J; Hirao K; Isobe M
JACC Cardiovasc Imaging; 2012 Apr; 5(4):422-9. PubMed ID: 22498333
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis.
Sobic-Saranovic DP; Grozdic IT; Videnovic-Ivanov J; Vucinic-Mihailovic V; Artiko VM; Saranovic DZ; Pavlovic SV; Obradovic VB
Clin Nucl Med; 2013 Jul; 38(7):516-21. PubMed ID: 23486337
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement.
Thi Hong Nguyen C; Kambe N; Kishimoto I; Ueda-Hayakawa I; Okamoto H
J Dermatol; 2017 Jul; 44(7):789-797. PubMed ID: 28295528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
